Hyperion Therapeutics, Inc. (Nasdaq: HPTX) today announced the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE